Notification pursuant to Section 28a of the Danish Securities Trading Act
9/3/2012 12:00 PM EST
Affitech A/S
Company Announcement
Notification pursuant to Section 28a of the Danish Securities Trading Act
Release no. 24/2012
Copenhagen and Oslo, 2012-09-03 18:00 CEST (GLOBE NEWSWIRE) --
Affitech has today received a major shareholder notification from Trans Nova
Investments Ltd., who in accordance with Section 28a of the Danish Securities
Trading Act, notifies, on behalf of Alexander Shuster, Chairman of the Board of
Directors of Affitech A/S, of the following transactions:
Name Trans Nova Investments Limited
--------------------------------------------------------------------------------
Reason for reporting Related party to Alexander Shuster, Chairman of
the Board of Affitech A/S
--------------------------------------------------------------------------------
Issuer and ISIN Affitech A/S/DK0015966592
--------------------------------------------------------------------------------
Type of transaction Purchase of shares
--------------------------------------------------------------------------------
Date of transaction 31st August, 2012
--------------------------------------------------------------------------------
Relevant market NASDAQ OMX COPENHAGEN A/S
--------------------------------------------------------------------------------
Number of traded securities 25,075,235 shares. Market value DKK 5,015,047
and market value
--------------------------------------------------------------------------------
Number of traded securities 408,853 shares. Market value DKK 75,760.46
and market value
--------------------------------------------------------------------------------
About Affitech
Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic
antibody company based in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The company utilizes a range of proprietary antibody technologies for
the discovery of fully human antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech’s premier discovery engine for the isolation of lead antibodies to
cell surface molecules in situ. Several of the Company's proprietary product
candidates were generated by CBAS™. Further information is available at
www.affitech.com.
Contact
Randi Krogsgaard, Director IR & Communications
Tel # +45 2320 1001, e-mail: